These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33939147)

  • 1. Impact of a Pilot Structured Mobile Technology Based Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease.
    Tincopa MA; Lyden A; Wong J; Jackson EA; Richardson C; Lok AS
    Dig Dis Sci; 2022 Feb; 67(2):481-491. PubMed ID: 33939147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer.
    Kenfield SA; Van Blarigan EL; Ameli N; Lavaki E; Cedars B; Paciorek AT; Monroy C; Tantum LK; Newton RU; Signorell C; Suh JH; Zhang L; Cooperberg MR; Carroll PR; Chan JM
    Eur Urol; 2019 Jun; 75(6):950-958. PubMed ID: 30638635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study.
    Pfirrmann D; Huber Y; Schattenberg JM; Simon P
    J Med Internet Res; 2019 Jan; 21(1):e11250. PubMed ID: 30602434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping.
    Hallsworth K; McPherson S; Anstee QM; Flynn D; Haigh L; Avery L
    J Med Internet Res; 2021 Jan; 23(1):e20491. PubMed ID: 33448929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?
    Montesi L; Caselli C; Centis E; Nuccitelli C; Moscatiello S; Suppini A; Marchesini G
    World J Gastroenterol; 2014 Aug; 20(29):10128-36. PubMed ID: 25110440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease.
    Gelli C; Tarocchi M; Abenavoli L; Di Renzo L; Galli A; De Lorenzo A
    World J Gastroenterol; 2017 May; 23(17):3150-3162. PubMed ID: 28533672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers.
    Mazzotti A; Caletti MT; Brodosi L; Di Domizio S; Forchielli ML; Petta S; Bugianesi E; Bianchi G; Marchesini G
    J Hepatol; 2018 Nov; 69(5):1155-1163. PubMed ID: 30290973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bariatric Surgery in Nonalcoholic Fatty Liver Disease (NAFLD): Impact Assessment Using Paired Liver Biopsy and Fibroscan.
    Agarwal L; Aggarwal S; Shalimar ; Yadav R; Dattagupta S; Garg H; Agarwal S
    Obes Surg; 2021 Feb; 31(2):617-626. PubMed ID: 33052552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study.
    Honda Y; Kessoku T; Sumida Y; Kobayashi T; Kato T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Kataoka K; Taguri M; Yamanaka T; Seko Y; Tanaka S; Saito S; Ono M; Oeda S; Eguchi Y; Aoi W; Sato K; Itoh Y; Nakajima A
    BMC Gastroenterol; 2017 Aug; 17(1):96. PubMed ID: 28789631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Text messaging approach improves weight loss in patients with nonalcoholic fatty liver disease: A randomized study.
    Axley P; Kodali S; Kuo YF; Ravi S; Seay T; Parikh NM; Singal AK
    Liver Int; 2018 May; 38(5):924-931. PubMed ID: 29117472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
    Lefere S; Dupont E; De Guchtenaere A; Van Biervliet S; Vande Velde S; Verhelst X; Devisscher L; Van Vlierberghe H; Geerts A; De Bruyne R
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2317-2326.e4. PubMed ID: 34871812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
    Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL
    J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.